DRREDDY:NSE
Dr Reddy's Laboratories Ltd
1 199,80 ₹
arrow_upward
+1,68%(+19,80) 1 d.
9. okt., 15:30:00 GMT+5:30 · INR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: DRREDDY…
Atvērt
1 180,00 ₹
Augsta
1 200,80 ₹
Zema
1 172,00 ₹
Tirgus kapitalizācija
997,09 mljrd.
Vid. apjoms
1,81 milj.
Apjoms
1,51 milj.
Dividende
0,67%
Ceturkšņa dividendes
2,00 ₹
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 10. jūl.
Cenas/peļņas attiecība
31,03
Augstākā 52 ned.
1 414,90 ₹
Zemākā 52 ned.
1 101,00 ₹
Peļņa uz vienu akciju
38,67 ₹
Apgrozībā esošās akcijas
166,06 milj.
Darbinieku skaits
28 tūkst.
Atvērt
1 180,00 ₹
Augsta
1 200,80 ₹
Zema
1 172,00 ₹
Tirgus kapitalizācija
997,09 mljrd.
Vid. apjoms
1,81 milj.
Apjoms
1,51 milj.
Dividende
0,67%
Ceturkšņa dividendes
2,00 ₹
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 10. jūl.
Cenas/peļņas attiecība
31,03
Augstākā 52 ned.
1 414,90 ₹
Zemākā 52 ned.
1 101,00 ₹
Peļņa uz vienu akciju
38,67 ₹
Apgrozībā esošās akcijas
166,06 milj.
Darbinieku skaits
28 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Seeking Alpha
·
pirms 14 minūtēm
15 Years In, I've Never Seen The S&P 500 Hide So Much Damage
Simply Wall Street
·
pirms 1 stundas
Low Valuation Could Change The Case For APA Stock (APA)
Forbes
·
pirms 44 minūtēm
Stock Market Crash Hits 54% Of Stocks—Is The S&P 500 Next?
Profils
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Par “Dr Reddy's Laboratories Ltd”
ĢenerāldirektorsErez Israeli
Darbinieki27,5 tūkst.
Dibināšanas datums1984
Galvenais birojsHaidarabada, Āndhra Pradēša, Indija
Sektors-
Tīmekļa vietnedrreddys.com